Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 18 2025 - 3:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission file number: 001-40231
Universe Pharmaceuticals INC
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development
Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Adjournment of Extraordinary General Meeting
On February 17, 2025, Universe Pharmaceuticals
INC (the “Company”) convened an extraordinary general meeting of shareholders (the “February 2025 Extraordinary General
Meeting”). However, due to lack of quorum, the February 2025 Extraordinary General Meeting was adjourned to February 19, 2025, at
10:00 a.m., Beijing Time at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji’an City, Jiangxi 343100,
the People’s Republic of China.
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Universe Pharmaceuticals INC. |
|
|
Date: February 18, 2025 |
By: |
/s/ Gang Lai |
|
|
Gang Lai |
|
|
Chief Executive Officer |
2
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Feb 2024 to Feb 2025